Potential conflict of interest: Nothing to report.
A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome†
Version of Record online: 1 JUN 2009
Copyright © 2009 Movement Disorder Society
Volume 24, Issue 10, pages 1445–1452, 30 July 2009
How to Cite
Grote, L., Leissner, L., Hedner, J. and Ulfberg, J. (2009), A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov. Disord., 24: 1445–1452. doi: 10.1002/mds.22562
- Issue online: 24 JUL 2009
- Version of Record online: 1 JUN 2009
- Manuscript Accepted: 26 FEB 2009
- Manuscript Revised: 11 FEB 2009
- Manuscript Received: 7 JUL 2008
- Renapharma Ltd, Uppsala, Sweden
Additional Supporting Information may be found in the online version of this article.
|MDS_22562_sm_SuppFig-1.doc||31K||Supporting Figure 1: Short-, intermediate-, and long-term effects of iron sucrose and placebo on RLS symptoms. Shown as the median values of the IRLS score at baseline (week 0) and at follow up weeks 3, 7, 11, and months 5, 8, and 12. (ITT analysis, n=29 for the iron sucrose group and n=31 for the placebo group)|
|MDS_22562_sm_SuppTable-1.doc||58K||Supporting Table 1: Adverse reactions during the study. Number of adverse reactions and percentage of all reported reactions listed in certain categories. Different events may have occurred in one individual patient and at repeated occasions.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.